NR2F1 and melanoma: Aberrant expression of NR2F1-AS1 has been documented in a wide array of malignancies, including breast [25–27], gastric [28–31], bladder [32–34], thyroid [35–37], liver [38–41], osteosarcoma [42, 43], lung [44], esophageal [45, 46], pancreatic [45, 46], neuroblastoma [47], melanoma [48], endometrial [49], colorectal [50], cervical [51], and thyroid [52] cancers.